Literature DB >> 30897304

Genetic studies on systemic lupus erythematosus in East Asia point to population differences in disease susceptibility.

Yong-Fei Wang1, Yu Lung Lau1, Wanling Yang1.   

Abstract

Systemic lupus erythematosus (SLE) is a prototype autoimmune disease with extreme clinical heterogeneity and significant differences between populations. East Asian populations are known to have higher prevalence and more severe clinical manifestations for SLE than Europeans. The difference could be the result of genetic and environmental factors, and the interactions between them. Thus, identifying genetic associations from diverse populations provides an opportunity to better understand the genetic architecture of this heterogeneous disease. It is also necessary to elucidate population differences and to apply the findings in future stratified treatment of the disease, with ethnicity likely a major factor to consider. Indeed, it has shown that there are significant differences between East Asians and European populations in several genetic loci for SLE. Genetic studies on SLE are very active in East Asian countries and there have been close collaborations among scientists in this region. Here, we document some work done in this region on SLE genetic research and discuss the aspect of population differences.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  East Asian; association studies; genetic susceptibility; population differences; systemic lupus erythematosus

Mesh:

Year:  2019        PMID: 30897304     DOI: 10.1002/ajmg.c.31696

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  4 in total

1.  Risk factors for 1-year hospital readmissions in patients with systemic lupus erythematosus.

Authors:  Jinxia Chen; Limin Zhang; Liutao Huang; Shuxian Chen; Yongzhi Xu; Huafeng Liu
Journal:  Clin Exp Med       Date:  2022-05-27       Impact factor: 3.984

2.  Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Haiping Xing; Haiyu Pang; Tian Du; Xufei Yang; Jing Zhang; Mengtao Li; Shuyang Zhang
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

3.  Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.

Authors:  Fengchun Zhang; Jie Zheng; Yang Li; Guochun Wang; Mingjun Wang; Yin Su; Jieruo Gu; Xingfu Li; Damon Bass; Myron Chu; Paula Curtis; Kathleen DeRose; Regina Kurrasch; Jenny Lowe; Paige Meizlik; David A Roth
Journal:  RMD Open       Date:  2022-04

4.  Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus.

Authors:  Tian Du; Haiyu Pang; Faming Ding; Yicong Ye; Mengtao Li; Xufei Yang; Yang Zhang; Xiaofeng Zeng; Shuyang Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.